Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.
The investment narrative surrounding Hims & Hers Health, Inc. presents a complex puzzle. On one hand, institutional money is flowing in and the company i ...
Zacks Investment Research on MSN
Investors heavily search Novo Nordisk A/S (NVO): Here is what you need to know
Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...
Ascendis Pharma's Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nearly quadrupling year-over-year. Read why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback